http://www.fpnotebook.com/
Hepatitis A VaccineAka: HAVRIX, VAQTA
- Indications
- All children as Primary Series at age 1 year
- New recommendation in U.S. as of 2006
- Children are reservoir for Hepatitis A
- May erradicate Hepatitis A from population
- Travelers to endemic Hepatitis A areas
- Children living in endemic states of United States
- Arizona (highest Prevalence in United States)
- Alaska
- Oregon
- New Mexico
- Utah
- Washington
- Oklahoma
- South Dakota
- Idaho
- Nevada
- California
- Food handlers
- Workers with primates
- Day care workers or children
- Illicit Drug use
- Homosexual male
- Chronic Liver Disease
- Clotting Factor disorder
- Preparation
- See also Twinrix
- Hepatitis A Vaccine (Havrix, Vaqta)
- Dosage
- Start vaccine at least 4 weeks before departure
- Administer Hepatitis A Immunoglobulin if less
- Children (ages 1 to 18 years)
- Dose 1: 0.5 ml IM at month 0
- Dose 2: 0.5 ml IM at month 6-12
- Adult (ages 19 years and older)
- Dose 1: 1 ml IM at month 0
- Dose 2: 1 ml IM at month 6-12
- Precautions
- Safe in HIV
- See Immunization in HIV
- Safe in Pregnancy
- See Immunization in Pregnancy
- Not indicated for under age 1 years
- Use Hepatitis A Immunoglobulin for exposure
- Efficacy
- Protective antibodies after dose 1
- Two weeks: 37% of patients
- Four weeks: >90% of patients
- Twenty-six weeks: 100% of patients
- Long-term protection occurs with dose 2
- Protection lasts at least 20 years after series
- References
- (2001) Med Lett Drugs Ther 43(1110):67
- Craig (2004) N Engl J Med 350:476
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
, Immunologic Factor (T129)
|
| English | Havrix |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree